Skip to content

A clinical trial to study the effect of Holy Basil on sleep quality in moderately stressed participants

A Prospective, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Ocimum tenuiflorum (Holy Basil) HolixerTM on sleep quality of adults experiencing moderate stress - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/10/059316
Enrollment
40
Registered
2023-10-31
Start date
Unknown
Completion date
Unknown
Last updated
2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: F438- Other reactions to severe stress

Interventions

Control Intervention1: Placebo: Micro crystal cellulose

Sponsors

International Institute of Sleep Sciences
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The following criteria are to be checked at the time of screening. The participant may only be included in the study if ALL the following statements are FULLFILLED: 1. With age of at least 18 years to 65 years 2. PSS score > 14 3. Have not taken any hypnotic medicines, Supplements within last 3 months. 4. Able to communicate and read in English. 5. Women of child-bearing potential (refer to appendix for definition) willing to use an adequate method of contraception to avoid pregnancy throughout the study period. 6. No Caffeine or Alcohol intake 12 hours prior to Polysomnogram study 7. Willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: Participants with heart disease, sleep disorders such as OSA and PLMD, with hepatic impairment, those working in shifts, history of drug abuse and on any sedating medications

Design outcomes

Primary

MeasureTime frame
Mean percent change in CAP rate between Baseline and Treatment sleep studyTimepoint: Visit 3 (baseline) and Visit 11 (8 weeks)

Secondary

MeasureTime frame
1.Change in PSS, ISI, RSQ-W and PSQI score 2. Changes in other Sleep parameters such as Total Sleep time, Sleep Efficiency, Stage 3 sleep, REM duration and REM latency 3.Adverse effects Timepoint: 1. Visit 1, Visit 7 and Visit 11 next day 2. Visit 3 and Visit 11 3. All visits

Countries

India

Contacts

Public ContactDr Nushafreen Irani

International Institute of Sleep Sciences

abhijitd1965@gmail.com8108558111

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026